Plus: Apple makes big claims about the effectiveness of its Lockdown Mode anti-spyware feature, Russia moves to implement ...

Joe Bradley is speaking out on Grace Lilly‘s second arrest in less than three months, as Lilly opened up in the latest ...

If you’ve ever watched Lily Collins on screen and thought, “How does her skin look like that?”, you’re not alone. The actress ...

Credit: Shutterstock If you hate sit-ups and planks as much as I do, I’ve got good news — they’re not essential when it comes ...

Eli Lilly has spent months signaling it would challenge Novo Nordisk’s oral GLP-1 franchise. Now it has data to back that up. According to lead investigator Dr. Julio Rosenstock, Lilly’s pill ...

It’s a good day to be the pharmaceutical giant Eli Lilly. Right now, Eli Lilly appears to be the leader in the GLP-1 race amid multiple difficult headwinds for Novo Nordisk. As of this writing, Novo ...

Determined to avoid a repeat of the supply shortfalls that plagued early GLP-1 rollouts for obesity, Eli Lilly has amassed a sizable store of its oral weight loss candidate orforglipron. Specifically, ...

Hims & Hers Health began advertising a $49 Ozempic pill lookalike last week -- then stopped. Novo Nordisk charges $149 for its own Wegovy pills. Lilly charges $299 for Zepbound shots. First, on Friday ...

Eli Lilly’s stock closed 10.3% higher on Wednesday after the drug giant reported triple-digit growth of Zepbound and Mounjaro, its game-changing weight-loss and Type 2 diabetes drugs. That’s the third ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

Both Novo Nordisk and Eli Lilly are grappling with pricing pressure in the U.S., but their 2026 outlooks are diverging sharply. While Novo is bracing for a sales decline, Lilly sees revenue charging ...

Eli Lilly is rated SELL due to lofty valuation, despite extraordinary execution and recent market leadership in GLP-1 and obesity drugs. LLY's current $950B market cap implies sustained 25% annual ...